Aslı DİLEKTAŞLI GÖREK, Banu Musaffa SALEPÇİ, Mustafa DÜGER, Ülkü AKTÜRK AKA, Nagihan KOÇAK DURMUŞ, Nuray OKTAY, Hale TAŞYIKAN ARIK, Aysun ŞENGÜL

Influenza and Pneumonia Vaccination Rates and Factors Affecting Vaccination among Patients with Chronic Obstructive Pulmonary Disease

Background: Influenza and pneumococcal vaccinations are recommended in chronic obstructive pulmonary disease patients to decrease associated risks at all stages. Although the prevalence of chronic obstructive pulmonary disease is high in our country, as previously reported, vaccination rates are low. Aims: To assess the vaccination rates of chronic obstructive pulmonary disease patients and factors that may affect these. Study Design: Multi-centre cross-sectional study. Methods: Patients admitted to the chest diseases clinics of six different centres between 1 February 2013 and 1 January 2014 with a pre-diagnosis of Chronic obstructive pulmonary disease according to the Global initiative for chronic obstructive lung disease criteria, who were in a stable condition were included in the study. The survey, which included demographic characteristics, socioeconomic status, severity of disease and vaccination information, was first tested on a small patient population before the study. The survey was completed by the investigators after obtaining written informed consent. Results: The average age of the 296 included patients was 66.3±9.3 years and 91.9% were male. Of these, 36.5% had the influenza vaccination and 14.1% had the pneumococcal vaccination. The most common reason for not being vaccinated was 'no recommendation by doctors': 57.2% in the case of influenza vaccinations, and 46.8% in the case of pneumococcal vaccinations. Both vaccination rates were significantly higher in those patients with comorbidities (influenza vaccination p0.05). Vaccination rates were significantly higher in those with a whitecollar occupation and higher education level, and who presented to a university hospital (p

PDF

___

Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370:741-50.
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. Plos Med 2006;3:e442.
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD Updated 2015. http:// www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Feb18. pdf.
Department of Health and Human Services Centers for Disease Control and Prevention: National Immunization Program Advisory Committee on Immunization Practices, 29-30 June 2006; Atlanta, GA. Record of the Proceedings. Available from: http://www.michigan.gov/documents/mdch/ AcipMinJun06_FB100.
Chiatti C, Barbadoro P, Marigliano A, Ricciardi A, Di Stanislao F, Prospero E. Determinants of influenza vaccination among the adult and older Italian population with chronic obstructive pulmonary disease: a secondary analysis of the multipurpose ISTAT survey on health and health care use. Hum Vaccin 2011;7:1021-5.
Ciblak MA. Grip Platformu. Influenza vaccination in Turkey: prevalence of risk groups, current vaccination status, factors influencing vaccine uptake and steps taken to increase vaccination rate. Vaccine 2013;31:518- 23.
Cimen P, Unlu M, Kirakli C, Katgi N, Ucsular FD, Ayranci A, et al. Should Patients With COPD Be Vaccinated? Respir Care 2015;60:239-43.
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.GOLD Updated 2013. http://www. goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20. pdf
Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46.
Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999;54:581-86.
Arinez-Fernandez MC, Carraco-Garrido P, Garcia-Carballo M, Hernandez-Barrera V, de Miguel AG, Jimenez-Garcia R. Determinants of pneumococcal vaccination among patients with chronic obstructive pulmonary disease in Spain. Hum Vaccin 2006;2:99-104.
Vandenbos F, Gal J, Radicchi B. Vaccination coverage against influenza and pneumococcus for patients admitted to a pulmonary care service. Rev Mal Respir 2013;30:746-51.
Biberoğlu K. Haydi Büyükler Aşıya. Actual Med 2006;14:18-26
Montserrat-Capdevila J, Godoy P, Marsal JR, Cruz I, Solanes M. Effectiveness of influenza vaccination in preventing hospital admission due to exacerbations of chronic obstructive pulmonary disease. Enferm Infecc Microbiol Clin 2014;32:70-5.
Damiani G, Federico B, Visca M, Agostini F, Ricciardi W. The impact of socioeconomic level on influenza vaccination among Italian adults and elderly: a cross-sectional study. Prev Med 2007;45:373-9.
Endrich MM, Blank PR, Szucs TD. Influenza vaccination uptake and socioeconomic determinants in 11 European countries. Vaccine 2009;27:4018-24.
Vozoris NT, Lougheed MD. Influenza vaccination among Canadians with chronic respiratory disease. Respir Med 2009;103:50-8.
Ford ES, Mannino DM, Williams SG. Asthma and influenza vaccination: findings from the 1999-2001 National Health Interview Surveys. Chest 2003;124:783-9.
Lu PJ, Singleton JA, Rangel MC, Wortley PM, Bridges CB. Influenza vaccination trends among adults 65 years or older in the United States, 1989-2002. Arch Intern Med 2005;165:1849-56.
Jiménez-García R, Hernández-Barrera V, Carrasco-Garrido P, de Andrés AL, de Miguel Diez J, de Miguel A. Coverage and predictors of adherence to influenza vaccination among Spanish children and adults with asthma Infection 2010;38:52-7.